Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Rein Therapeutics Inc (Rein), formerly Aileron Therapeutics Inc, is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of orphan pulmonary and fibrosis indications. The company's pipeline products include LTI-03 novel treatments for idiopathic pulmonary fibrosis (IPF); LTI-01for loculated pleural effusion (LPE); LTI-05 targets cystic fibrosis. Its preclinical programs target cystic fibrosis and a peptide program focused on the Cav1 protein for systemic fibrosis indications. Rein is headquartered in Austin, Texas, the US.
Headquarters
United States of America
Address
Suite 250, Unit 390, 12407 North Mopac Expy, Austin, Texas, 78758
Website
www.reintx.com
Telephone
1 737 8021989
No of Employees
10
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RNTX (NASD)
EPS
XYZ
Net Income (2024)
XYZ
20.7%
(2024 vs 2023)
Market Cap*
$67.5M
Net Profit Margin (0 vs)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Rein Therapeutics |
| LTI-03: Idiopathic Pulmonary Fibrosis | |
| LTI-01: Loculated Pleural Effusion | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In October, the company entered into an agreement to sell ALRN-6924 to Advancium Health Network. |
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company acquired Lung Therapeutics, Inc., a biopharmaceutical company. |
| 2018 | Contracts/Agreements | In November, the company collaborated with Pfizer to evaluate ALRN-6924 in combination with Ibrance (palbociclib) to treat MDM2-Amplified Cancers. |
Competitor Comparison
| Key Parameters | Rein Therapeutics Inc | Black Diamond Therapeutics Inc | Abeona Therapeutics Inc | Seelos Therapeutics, Inc. | Lohocla Research Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Austin | Cambridge | Cleveland | New York City | Aurora |
| State/Province | Texas | Massachusetts | Ohio | New York | Colorado |
| No. of Employees | 10 | 21 | 226 | 8 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Josef H. Von RickenBach | Chairman | Executive Board | 2019 | 70 |
| Brian Windsor, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2024 | 59 |
| Cory Hogaboam, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Ron Chen | Controller - Corporate; Vice President - Finance | Senior Management | - | - |
| Timothy M. Cunningham | Chief Financial Officer - Interim | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer